PMID- 20950224
OWN - NLM
STAT- MEDLINE
DCOM- 20110228
LR  - 20171116
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 11
IP  - 18
DP  - 2010 Dec
TI  - An open-label comparison of the efficacy and safety of certoparin versus 
      unfractionated heparin for the prevention of thromboembolic complications in 
      acutely ill medical patients: CERTAIN.
PG  - 2953-61
LID - 10.1517/14656566.2010.521498 [doi]
AB  - OBJECTIVE: Guidelines recommend low-dose unfractionated heparin (UFH) and 
      low-molecular-weight heparin for the prophylaxis of venous thromboembolism (VTE) 
      in acutely ill medical patients. We report the findings of an open-label, 
      active-controlled, multicenter study in acutely ill medical patients comparing 
      certoparin and UFH. RESEARCH DESIGN AND METHODS: Open-label, active-controlled, 
      multicenter study. Patients received certoparin 3000 IU daily or UFH 7500 IU 
      twice daily. MAIN OUTCOME MEASURES: The primary endpoint was a composite of 
      symptomatic or asymptomatic proximal or distal deep vein thrombosis, symptomatic 
      pulmonary embolism, or VTE-related death. RESULTS: 172 patients were randomized 
      to UFH and 163 to certoparin for 8.5 +/- 2.1 days. The incidence of the primary 
      endpoint was 18.0% in patients receiving UFH and 10.7% with certoparin [absolute 
      difference -7.3; 95% confidence interval (CI) -16.9 to 2.3; p = 0.1353]. The 
      incidence during follow-up was 2.6% in the UFH and 2.0% in the certoparin group 
      (absolute difference -0.6; 95%CI -4.0 to 2.8; p = 0.7150). Major bleeding events 
      occurred in three patients with UFH and one patient with certoparin. CONCLUSIONS: 
      In acutely ill medical patients of at least 40 years of age, thromboprophylaxis 
      with certoparin 3000 IU daily is effective and safe in comparison with 7500 IU 
      twice daily UFH.
FAU - Schellong, Sebastian M
AU  - Schellong SM
AD  - Head of Medical Clinic II, Municipal Hospital of Dresden Friedrichstadt, Dresden, 
      Germany. schellong-se@khdf.de
FAU - Haas, Sylvia
AU  - Haas S
FAU - Greinacher, Andreas
AU  - Greinacher A
FAU - Schwanebeck, Uta
AU  - Schwanebeck U
FAU - Sieder, Christian
AU  - Sieder C
FAU - Abletshauser, Claudia
AU  - Abletshauser C
FAU - Bramlage, Peter
AU  - Bramlage P
FAU - Riess, Hanno
AU  - Riess H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20101018
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - V72OT3K19I (certoparin)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Heparin/adverse effects/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Practice Guidelines as Topic
MH  - Pulmonary Embolism/prevention & control
MH  - Venous Thromboembolism/*prevention & control
MH  - Venous Thrombosis/prevention & control
EDAT- 2010/10/19 06:00
MHDA- 2011/03/01 06:00
CRDT- 2010/10/19 06:00
PHST- 2010/10/19 06:00 [entrez]
PHST- 2010/10/19 06:00 [pubmed]
PHST- 2011/03/01 06:00 [medline]
AID - 10.1517/14656566.2010.521498 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2010 Dec;11(18):2953-61. doi: 
      10.1517/14656566.2010.521498. Epub 2010 Oct 18.